Stock Price & Analysis

Analysis and Insights

To determine whether it’s a good time to buy or sell NVAX stock, we need to analyze both technical and fundamental factors.

Technical Analysis:

NVAX's stock price has been experiencing a bearish trend recently, with significant resistance around the $8.00 mark. The latest candlestick chart shows a potential continuation of the downtrend, indicating a possible short-term downside.

Valuation Analysis:

NVAX currently has a P/E ratio of -8.91, which is lower than the average for the biotechnology sector, typically around 20-30. This suggests that investors are pricing in lower growth expectations, which might indicate undervaluation or negative sentiment.

Sentiment and Analyst Ratings:

Analyst sentiment is mixed. While some analysts remain positive about NVAX’s pipeline and vaccine development, others express concerns about its ability to scale production efficiently. Based on recent analyst ratings, NVAX has a consensus hold, but it's important to consider the high-risk/reward profile.

Conclusion:

Given the bearish technical indicators and mixed analyst sentiment, NVAX stock might not be the best buy at this time. However, if you're willing to accept potential price fluctuations for long-term growth, it could still be a good option. Consider waiting for a price dip or a confirmation of an uptrend before entering the market.

NVAX stock is predicted to reach $9.05 by 2025, driven by its inclusion in the Vanguard Small-Cap ETF with a 24.60% upside potential. The stock's technical indicators and Fibonacci levels suggest a bullish trend, targeting the resistance level of $9.05. Analysts also expect NVAX to reach $16.43, reflecting strong confidence in its growth.

The S1 support level for NVAX Stock is $6.57 ,The R1 resistant level for NVAX Stock is $8.16.

As of the end of day on 2025-04-01, the price of NVAX Stock was $6.09.

The target price for NVAX Stock according to analyst rating is 14.75, with the highest price target at 19.00 and the lowest at 9.00. Analysts have a Moderate Buy rating on NVAX Stock overall.

The market cap of NVAX is $1.0B.

NVAX is not overvalued based on its current metrics. Its EV/EBITDA of 1.71 and PS ratio of 0.57 suggest undervaluation. The stock price of $7.62 reflects moderate valuation. Analysts expect significant upside, with a target of $16.43. The company's focus on vaccine development supports long-term growth.

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.

NVAX stock is predicted to reach $15 by 2030, driven by its strong pipeline of vaccines and potential market expansion.

NVAX has a total of 1543 employees.